ESMO 2020 — Opening the door to first-line immunotherapy in advanced gastroesophageal cancers


  • Cristina Ferrario — Agenzia Zoe
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • First-line nivolumab+chemotherapy yields improved OS and PFS compared with chemotherapy alone in previously untreated patients with advanced gastric cancer (GC)/gastroesophageal junction cancer (GEJC)/esophageal adenocarcinoma (EAC).
  • The safety profile in this trial was manageable.
  • This combination is a potential new standard first-line treatment in this population.

Why this matters

  • Survival is poor after standard first-line chemotherapy in patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative GC/GEJC.

Study design

  • Randomized, open-label phase 3 study (CheckMate 649).
  • Previously untreated patients with unresectable or metastatic GC/GEJC/EAC without known HER2-positive status enrolled regardless of programmed cell death ligand 1 (PD-L1) expression.
  • Randomization (1:1:1):
    • Nivolumab+chemotherapy (data not reported here);
    • Nivolumab (360 mg 3×/week or 240 mg 2×/week) + chemotherapy (XELOX: oxaliplatin and capecitabine 3×/week or FOLFOX: fluorouracil, leucovorin, and oxaliplatin 2×/week); or
    • Chemotherapy alone.
  • 1581 patients concurrently randomly assigned to nivolumab+chemotherapy or chemotherapy alone.
  • Dual primary endpoint: OS and PFS in patients with PD-L1 combined positive score (CPS) ≥5.
  • Secondary endpoints: OS (PD-L1 CPS ≥1 or all randomized), OS (PD-L1 CPS ≥10), PFS (PD-L1 CPS ≥10, 1 or all randomized), objective response rate.
  • Funding: Bristol-Myers Squibb.

Key results

  • Minimum follow-up: 12 months.
  • Median OS (interim analysis) in PD-L1 CPS ≥5 tumors:
    • 14.4 months with the combination vs 11.1 months with chemotherapy only.
    • HR, 0.71 (P<.0001>
  • Median PFS (final analysis):
    • 7.7 months with the combination vs 6.1 months with chemotherapy only. 
    • HR, 0.68 (P<.0001>
  • Superior OS and PFS benefit also in PD-L1 CPS ≥1 and all randomly allocated patients with the combination vs chemotherapy alone.
  • No new safety concerns emerged with the combination (no grade 5 treatment-related adverse events).

Expert commentary

“These results are likely to lead a paradigm shift in the treatment of first-line advance gastroesophageal cancers. For patients with PD-L1 CPS ≥1, breaking through the 1-year barrier in OS is a milestone,” commented Elizabeth Smyth, medical oncologist, Cambridge University Hospitals NHS Foundation Trust, who was not involved in the study.

Follow all ESMO 2020 coverage on   Univadis .